Industry Insights
Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.
Oncology Trial Evidence: Survival, Combination Effects and Study OperationsConnect FDA oncology guidance on survival, component contribution, radiopharmaceutical safety, biopsies and patient outcomes to traceable study operations.
Adaptive and Bayesian Trials: From Statistical Design to Controlled OperationsConnect adaptive and Bayesian trial guidance to justified simulation, independent monitoring, controlled data handoffs and reproducible study operations.
BIMO Inspection or Remote Assessment? Build the Response Around the Actual Request (2026)Classify BIMO inspections, mandatory requests and voluntary remote assessments, then route the actual deadline, access scope and response evidence to an owner.
FDA's 2026 CGM and Immunogenicity-PK Specifications: Preserve the Path from Source to AnalysisDistinguish source observations, missing records and analysis derivations when implementing FDA’s 2026 CGM and immunogenicity-PK dataset recommendations.
COA Qualification and eCOA Release: Keep the Evidence Status Attached to the Instrument (2026)Separate COA qualification, submissions and Compendium evidence, then preserve the instrument’s context of use, version and permission in an eCOA release.
FDA Participation Guidance: Build a Distinct Handoff for Rare-Disease Re-Enrollment (2026)Turn FDA’s rare-disease re-enrollment recommendation into a protocol-specific handoff while preserving prior exposure, selection-bias and authorized-access limits.
Decentralized Trial Elements: Evidence, Oversight and Country Review (2026)Map remote trial activities to evidence, oversight and country-specific requirements using FDA guidance, ICH E6(R3) Annex 2 and a documented implementation review.
Multiregional Clinical Trials With China Sites in 2026: HGR Approval, PIPL Data Export and What the Registries ShowMap HGR, personal-information exports and hosting decisions for China-inclusive multiregional trials, with bounded registry evidence and practical regulatory checks.